A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia

NCT ID: NCT02875678

Last Updated: 2017-09-07

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-11-22
• Study Completion Date: 2017-08-07

Brief Summary

A Single-Dose Study to Evaluate the Effects of ABX-1431 on Gastric Accommodation and Nutrient Volume Tolerance in Patients with Functional Dyspepsia.

Detailed Description

This is a single dose, randomized, placebo-controlled, two period crossover study. This study will assess the effects of ABX-1431 on gastric physiology in patients with functional dyspepsia, who have clinical evidence of impaired gastric accommodation with meals.

All patients will undergo a screening visit for enrollment criteria. Eligible patients will be treated with a single dose of ABX-1431 HCl or placebo followed by IGP measurement, measured with a high resolution manometry probe during a nutrient volume tolerance test. After a washout period of at least one week, patients will undergo identical procedures with the other treatment.

This study will enroll 12 functional dyspepsia (FD) patients.

Conditions

Dyspepsia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

ABX-1431

ABX-1431, capsules, 40 mg, single dose

Group Type: EXPERIMENTAL

ABX-1431

Intervention Type: DRUG

Single-dose ABX-1431

Placebo

Placebo, capsules, single dose

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Single-dose matching placebo

Interventions

ABX-1431

Single-dose ABX-1431

Intervention Type: DRUG

Placebo

Single-dose matching placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patient has functional dyspepsia, postprandial distress syndrome (PDS) subtype, defined by the Rome III criteria.
• Patient has evidence of impaired gastric accommodation.
• Patient's Rome III Questionnaire results indicates that the intensity of co-existing epigastric pain and/or epigastric burning may be present, but have the same or lesser intensity than the evaluations of postprandial fullness or early satiety (i.e. epigastric pain and burning are not the prominent symptoms of the patient's functional dyspepsia).
• Patient recall of symptoms of gastrointestinal reflux over the past 8 weeks has no more than 2 episodes per week of heartburn or regurgitation.
• Patient is a male or female between 18 and 65 years of age at the pre-study/screening visit.
• Patient has a Body Mass Index (BMI) >18 to ≤30 kg/m2 at the pre-study/screening visit.
• Patient is judged to have no unmanaged significant disease or disorder based on medical history, physical examination, vital sign measurements, and laboratory safety obtained at pre-study/screening, and within 36 hours prior to first administration of study drug.
• Patient has no clinically significant abnormality of ECG performed at pre study/screening, and prior to first administration of study drug.
• Patient is willing to undergo the nutrient volume tolerance tests.

Exclusion Criteria

• Patient is under the age of legal consent.
• Female patients who are pregnant or breastfeeding.
• Patient has a personal history of a clinically significant psychiatric disorder (including severe affective disorder, anxiety disorder, post-traumatic stress disorder, psychotic disorder or drug-induced psychoses).
• Patient has a first-degree family history of schizophrenia, severe affective disorder, severe anxiety disorder, or other psychosis.
• Patient is taking antidepressants including SSRIs, SNRIs, tricyclic antidepressants, or atypical antidepressant medications such as bupropion, mirtazapine, trazodone or agomelatine. Patients taking these or other types of medicine for anxiety are also excluded. Patients who have discontinued antidepressants more than 6 months ago may be enrolled at the discretion of the Investigator. Patients who are taking gabapentin or pregabalin or buspirone are also excluded.
• Patient is mentally or legally incapacitated, has significant emotional problems at the time of pre-study/screening visit or is expected to have potential for mental incapacitation during the conduct of the study.
• Patient has had any gastrointestinal surgery. Those having undergone a simple appendectomy more than 1 year prior to the pre-study/screening visit may participate.
• Patient has had any acute gastrointestinal illness in the past 3 months.
• Patient has laboratory tests at screening or within 36 hours of first administration of study drug outside of these limits: Aspartate transaminase (AST) >1.5 x upper limit of normal (ULN) or Alanine transaminase (ALT) >1.5 x ULN.
• Patient has an estimated creatinine clearance (CrCl) of ≤80 mL/min based on the Cockcroft-Gault equation. An actual creatinine clearance, as measured using a 24-hour urine collection, may be used in place of, or in conjunction with the Cockcraft-Gault calculation. Patients with an actual or calculated creatinine clearance that is in the range of 72-79 mL/min (i.e., within 10% of 80 mL/min) may be enrolled in the study at the discretion of the Investigator.
• Patient has an active or prior history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches.
• Patient has a history of clinically significant neoplastic disease, with the exception of adequately treated localized or in situ non-melanoma carcinoma of the skin (e.g., basal cell carcinoma) or the cervix.
• Patient has a family history of long QT syndrome.
• Patient has a QTc interval of >450 msec (male patients) or >470 msec (female patients).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abide Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Chan Beals, MD,PhD

Role: STUDY_DIRECTOR

Abide Therapeutics

Locations

UZ Leuven

Leuven, , Belgium

Countries

Belgium

Other Identifiers

ABX-1431_PN005

Identifier Type: -

Identifier Source: org_study_id